Clinical utility of 188Rhenium-hydroxyethylidene-1,1-diphosphonate as a bone pain palliative in multiple malignancies
Ajit Shinto(Kovai Medical Center and Hospital), Ashutosh Dash(Bhabha Atomic Research Centre), Mythili Kameswaran(Tata Memorial Hospital), Jephy Joseph(Kovai Medical Center and Hospital), Ezhil Radhakrishnan(Nova Medical (United States)), Madhava B. Mallia(Bhabha Atomic Research Centre), Indira Upadhyay(Nova Medical (United States)), Rajeshwari Subramaniam(Kovai Medical Center and Hospital), Madhu Sairam(Kovai Medical Center and Hospital), Koramadai Karuppusamy Kamaleshwaran(Kovai Medical Center and Hospital), Sharmila Banerjee(Bhabha Atomic Research Centre)
Cited by 15
Related Papers
Production of 177Lu for Targeted Radionuclide Therapy: Available Options
|Nuclear Medicine and Molecular Imaging|2015|375
Sustained Availability of <sup>99m</sup>Tc: Possible Paths Forward
|Journal of Nuclear Medicine|2012|140
Peptide Receptor Radionuclide Therapy: An Overview
|Cancer Biotherapy and Radiopharmaceuticals|2015|122
Targeted Radionuclide Therapy - An Overview
|Current Radiopharmaceuticals|2013|117
Development of an electrochemical 90Sr–90Y generator for separation of 90Y suitable for targeted therapy
|Nuclear Medicine and Biology|2008|99